Journal article icon

Journal article

Counterpoint: Should an attempt be made to withdraw inhaled corticosteroids in all patients with stable GOLD 3 (30% ≤ FEV1 < 50% predicted) COPD? No.

Abstract:

Inhaled corticosteroids (ICS) have been accepted by successive GOLD documents as being effective agents for the prevention of COPD exacerbations and decline in health status. The combination of an ICS and a long-acting beta-agonist (LABA) is superior to the LABA alone in achieving these positive benefits. As the major effect of adding ICS is to reduce exacerbations, conventional guidance suggests this treatment in patients with a history of prior exacerbations. However, there has been a reapp...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/j.chest.2018.01.030

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Target Discovery Institute
Oxford college:
St Edmund Hall
Role:
Author
Publisher:
Elsevier
Journal:
Chest More from this journal
Volume:
153
Issue:
4
Pages:
782-784
Publication date:
2018-02-02
Acceptance date:
2018-01-11
DOI:
EISSN:
1931-3543
ISSN:
0012-3692
Pmid:
29410364
Language:
English
Pubs id:
pubs:823382
UUID:
uuid:1cc52c14-4f75-4952-9813-6b0b1a9d354d
Local pid:
pubs:823382
Source identifiers:
823382
Deposit date:
2018-02-13

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP